Recently funded awards

This page features a selection of investigator-led programmes, projects and fellowships that we have supported through our response-mode grant funding schemes at recent committee meetings.

Select a funding committee below to see what they have funded recently:

Advanced Clinician Scientist Fellowships

Gerhardt Attard, The Institute of Cancer Research

Biomarker-directed treatment of metastatic prostate cancer

James O'Connor, University of Manchester

Translating MRI biomarkers for clinical decision making in lung cancer

 

Clinician Scientist Fellowships

Richard Bryant, University of Oxford

Combining Minimally Invasive Interventions with Radiotherapy to Improve Outcomes and Reduce Treatment Toxicity and Side-Effects in Locally Advanced Prostate Cancer

Jessica Okosun, Queen Mary, University of London

Definition and Functional Characterisation of Follicular Lymphoma-propagating cell populations

Marnix Jansen, University College London

Landscaping the Barrett’s terrain: stem cell evolution in oesophageal cancer progression and recurrence

 

Postdoctoral Research Bursaries

Sacheen Kumar, Imperial College London

Investigation of the influence of the microbiome on the production of Volatile Organic Compounds in Oesophago-gastric adenocarcinoma

Aidan Rose, University of Dundee

Investigating The Role of Pro-Oncogenic Activin Mediated Migration and Invasion in Human Cutaneous Squamous Cell Carcinoma

Adel Samson, University of Leeds

Combination Oncolytic Reovirus and Sorafenib for Hepatocellular Carcinoma; rebalancing sorafenib induced immunosuppression through targeted virus-mediated interferon stimulation

Biomarker Project Awards

Ghulam Mufti, King's College London

Identification of the pathogenetic genomic signature that predicts for dysplastic and leukaemic transformation in severe aplastic anaemia following treatment with eltrombopag

 

Feasibility Study Awards

Andrew Tutt, The Institute of Cancer Research

PHOENIX: A preoperative “window of opportunity” phase 2a biomarker endpoint trial of FAK or P13K/MTORC1/2 inhibition in patients with post-neoadjuvant chemotherapy resistant residual triple-negative breast cancer (TNBC)

Adele Francis, University of Birmingham

NOSTRA-Feasibility: A non-randomised Feasibility Study to assess if patients with residual cancer following dual targeted neoadjuvant treatment for ER-negative HER2-positive early breast cancer can be identified by multiple Ultrasound Scan (USS)-directed tumour-bed biopsies?

Nicholas Turner and Judith Bliss, The Institute of Cancer Research

c-TRAK: A randomised trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with high risk early breast cancer

Zoltan Takats and Daniel Leff, Imperial College London

Rapid Evaporative Ionisation Mass Spectrometry for Examination of Circumferential Surgical Excision Margins [REI-EXCISE Trial]

 

Late Phase Clinical Trial Awards

Ujjal Mallick, University College London

IoN: Is ablative radioiodine Necessary for low risk differentiated thyroid cancer patients - a randomised trial

Graham Jackson and Gordon Cook, University of Leeds

FITNEsS (Myeloma XIV): Frailty-adjusted therapy In Transplant Non-Eligible patients with newly diagnosed Symptomatic myeloma

Andrew Pettitt, University of Liverpool

PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma (PETReA)

Dean Fennell and Gareth Griffiths, University of Southampton

CONFIRM: CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma: A phase 3 trial to evaluate the efficacy of nivolumab

Fiona McDonald and Judith Bliss, The Institute of Cancer Research

HALT: Targeted therapy beyond progression with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene Addicted Lung Tumours (HALT)

Emma Hall and Isabel Syndikus, The Institute of Cancer Research

PIVOTALboost: A phase 3 trial of prostate alone vs pelvic lymph node IMRT with or without prostate boost for intermediate and high risk localised prostate cancer

Biotherapeutics Programme Awards

Alan Melcher and Kevin Harrington, The Institute of Cancer Research

Combination Immunovirotherapy, Checkpoint Inhibition And Clinical Standard Of Care For The Treatment Of Metastatic Melanoma

 

Biotherapeutics Project Awards

Francesco Crea, The Open University

Long non-coding RNAs implicated in neuroendocrine prostate cancer initiation and progression: novel therapeutic targets for an incurable disease

Francis Mussai and Carmela De Santo, University of Birmingham

Engineering immune suppression-resistant anti-GD2 CAR T cells for neuroblastoma

 

Small Molecule Project Awards

Sarah Blagden, University of Oxford

Targeting LARP1 to overcome acquired treatment resistance in cancer

Sibylle Mittnacht, University College London

Identification of proximal phosphorylation targets engaged by Ser/Thr protein kinase TP53RK involved in protection of TP53 positive cancer cells to genotoxic and antimitotic therapies

Rahul Roychoudhuri, Babraham Institute

Identifying small molecule inhibitors of the transcription factor BACH2 for immune-based therapy of cancer

Project Awards

Katriina Whitaker, University of Surrey

Understanding socioeconomic differences in help-seeking for breast cancer symptoms in the UK

Julie Walabyeki and Una Macleod, University of Hull

Age linked factors and help seeking behaviour: a qualitative study exploring the effect of older people's fatalistic attitudes towards ill health and dying

Sara Macdonald and Shona Hilton, University of Glasgow

An exploration of the media representation of cancer and its impact on older adults' understanding of cancer risk and help-seeking behaviour

Cristina Renzi, University College London

Missed opportunities for earlier cancer diagnosis along the diagnostic pathway and effect on colorectal cancer diagnosis following emergency presentation: importance of healthcare and patient-related factors

David Weller and Domenica Coxon, University of Edinburgh

Understanding how 'lung cancer symptoms' and 'service' factors drive the decision to seek help from a GP in the Scottish public: a discrete choice experiment

Drug Development Projects

Fiona Collinson and David Anthoney, University of Leeds

Preclinical development and a phase 1 first in human clinical trial of TYG100 a novel rationally designed recombinant vaccine targeted to antigen presenting cells and stimulating gastrin neutralising antibodies, in the treatment of pancreatic and gastro-oesophageal cancer.

 

Preclinical Combination Grants

James Arnold, King's College London

The investigation of pharmacodynamic markers associated with heme oxygenase-1 inhibition improving the efficacy of chemotherapeutics in the treatment of cancer

Ilaria Bellantuono, University of Sheffield

Preclinical testing of zoledronate to reduce radiation-induced enteritis

Udai Banerji, The Institute of Cancer Research

In vitro and in vivo assessment of the combination of the WEE1 inhibitor, AZD1775, and the CHK1 inhibitor, CCT245737

 

Trial Grants

Yvette Drew, University of Glasgow

CRUKD/16/014 PRIMROSE Phase 1b/2 open label, multi-centre, dose escalation trial of oral PARP inhibitor rucaparib in combination with oral dual pan-class 1 PI3-Kinase/mTOR inhibitor VS5584 in patients with advanced solid tumours & dose expansion cohorts in high grade ovarian cancers & endometrial cancer

Josef Vormoor, University of Birmingham

CRUKD/16/015 SeluDex: A phase 1/2 expansion study of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated adult and paediatric ALL

Simon Crabb, University of Southampton

CRUKD/17/007 A phase 1b/2a trial to combine the CSF1 receptor inhibitor PLX3397 with the new generation AR antagonist enzalutamide in metastatic castration resistant prostate cancer

Emma Dean, University of Glasgow

CRUKDE/17/006 PAGoDA: A phase 1b trial combining the selective dual Trk/Fms kinase inhibitor PLX-7486 with gemcitabine in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

Sean Lim, University of Southampton

CRUKD/17/008 RIVA: A phase 2a study of rituximab and varlilumab in relapsed or refractory B-cell malignancies.

Adel Samson and Alan Melcher, University of Leeds

CRUKD/17/010 Intravenous HSV1716 Ahead of Planned Surgical Resection for High Grade Brain Tumours.

Career Development Fellowship

Constance Alabert, University of Dundee

Chromatin replication and cancer

Noor Gammoh, University of Edinburgh

Role of autophagy in glioblastoma progression and survival

Inigo Martincorena, Wellcome Trust Sanger Institute

Dissecting the earliest steps in pancreatic cancer by genomic analyses of normal and precancerous tissue

Luca Magnani, Imperial College London

Systematic functional characterization of somatic regulatory mutations driving estrogen receptor positive breast cancer progression.

Evropi Theodoratou, University of Edinburgh

Colorectal cancer reduction through risk stratification of screening, follow-up and treatment

Laureano de la Vega, University of Dundee

HIPK2 as a novel determinant of cancer therapeutic resistance

 

Career Establishment Award

Yinyin Yuan, The Institute of Cancer Research

Deciphering the microenvironmental niches of lung cancer evolution

Andrea Sottoriva, The Institute of Cancer Research

Evolutionary forecasting of prostate cancer recurrence within a clinical trial

 

Senior Cancer Research Fellowship

Sergio Quezada, University College London

Deciphering the Immune and Neoantigen Landscape In NSCLC and Their Relevance to Cancer Immunotherapy

George Vassiliou, Wellcome Trust Sanger Institute

Investigation of the molecular pathogenesis and therapeutic vulnerabilities of acute myeloid leukaemia using genome-editing technologies

Programme Awards

David Adams and Allan Balmain, Wellcome Trust Sanger Institute

Mutational signatures of lung cancer development in response to environmental carcinogens

John Ladbury, University of Leeds

Characterisation of cancer of non-genetic origin (CONGO): oncogenic signalling initiated through non-activated receptors

Martin Humphries, University of Manchester

Stromal rigidity as a driver of pancreatic cancer cell proliferation

Anthony Green and Berthold Gottgens, University of Cambridge

The transcriptional programs of myeloproliferative neoplasms (renewal)

Ronald Hay, University of Dundee

Harnessing the PML-SUMO-RNF4 axis for cancer therapy (renewal)

Neil Perkins, Newcastle University

NF-kappaB regulated signalling pathways that control tumourigenesis and the response to cancer therapy (renewal)

 

Programme Foundation Awards

Stuart McDonald, Queen Mary, University of London

Investigating the role of gland phenotype in the evolution of Barrett’s oesophagus to dysplasia

Alessandro Vannini, The Institute of Cancer Research

Understanding Brf2-dependent RNA Polymerase III transcription in cancer: structures, mechanisms and potential for intervention

Igor Vivanco, The Institute of Cancer Research

Characterization of the non-catalytic functions of AKT and other AGC kinases in cancer

Ivan Ahel, University of Oxford

Understanding the function of MACROD1 and MACROD2 proteins and their relevance to cancer

 

Cancer Immunology Project Awards

Stephen Anderton, University of Edinburgh

Inflammatory mechanisms to suppress Treg cell function in cancer

George Kassiotis, The Francis Crick Institute

When immune targeting of endogenous retroviral antigens destroys or spreads a tumour

Tilman Sanchez-Elsner, University of Southampton

Tumour-derived microRNAs control macrophages in the immune response to human lung tumours

 

Multidisciplinary Project Awards

Simon Ameer-Beg and Tony Ng, King's College London

Multimodal Advanced Optical Imaging To Probe Plasma Exosomes For ErbB Receptor Network Rewiring: A Potential Treatment Resistance Mechanism In Lung Cancers

Trevor Dale and Paola Borri, Cardiff University

Using CARS microscopy to realise the potential of 3D culture for personalised medicine and drug discovery

Richard Day and Simon Gaisford, University College London

A Novel Drug-Device Adjuvant Treatment for Radical Prostatectomy

Daniel Frankel and Kenneth Rankin, Newcastle University

Determining and exploiting the anti-cancer properties of naked mole-rat hyaluronan

Emad Moeendarbary and Fernando Calvo, University College London

Investigating the physical and biological determinants of cancer cell extravasation

Mengxing Tang and Eric Aboagye, Imperial College London

3D ultrafast ultrasound with microbubble contrast agents for simultaneous imaging of molecular targets and perfusion in cancer

Project Grants

Jenny Hatchard, University of Bath

Voices in fiscal cancer prevention: An investigation of non-governmental organisations and networks engaged in tobacco, alcohol and sugar-related taxation and price policy debates in the UK

Felix Naughton, University of East Anglia

Smoking cessation advice in primary care; what does it comprise of and does it make a difference?

Caitlin Notley, University of East Anglia

Real world experiences of using e-cigarettes for avoiding relapse to smoking: success or failure. A qualitative study

More facts and figures about our research funding

Funding by location map

Find out more about how and where we supported research in the last year with our interactive map and infographics.

Funding committees

Successful applicant case studies

Find out how our current grantees successfully applied for funding.

Read more

Our Research Prizes

Do you know somebody whose exceptional research merits reward and recognition? Nominate the rising stars and inspiring leaders of cancer research for our Research Prizes by 31 March.

Find out more

Share this page